Skip to main content
. Author manuscript; available in PMC: 2021 Jun 29.
Published in final edited form as: Curr Oncol Rep. 2013 Jun;15(3):232–238. doi: 10.1007/s11912-013-0309-5

Table 1.

Risk stratification of newly diagnosed patients (International Germ Cell Consensus Classification)

Non-seminoma Seminoma
Low risk

  • Testis or retroperitoneal primary, and

  • No non-pulmonary visceral metastases and

  • Good markers (AFP<1,000 ng/mL and B-HCG<5,000 IU/L and LDH<1.5 ULN)

  • 56 % patients

  • 90 % EFS at 5 years

  • Any primary site, and

  • No non-pulmonary visceral metastases and

  • Normal AFP, any B-HCG, any LDH

  • 90 % patients

  • 80 % EFS at 5 years
Intermediate risk

  • Testis or retroperitoneal primary, and

  • No non-pulmonary visceral metastases and

  • Intermediate markers (AFP 1,000-10,000 ng/mL or B-HCG 5,000-50,000 IU/L or LDH 1.5-10 ULN)

  • 28 % patients

  • 80 % EFS at 5 years

  • Testis or retroperitoneal primary, and

  • Non-pulmonary visceral metastases and

  • Normal AFP, any B-HCG, any LDH

  • 10 % patients

  • 67 % EFS at 5 years
Poor risk

  • Mediastinal primary, or

  • Non-pulmonary visceral metastases or

  • Poor markers (AFP >10,000 ng/mL or B-HCG >50,000 IU/L or LDH >10 ULN)

  • 56 % patients

  • 50 % EFS at 5 years

ULN: Upper limit of normal